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ABSTRACT
Henoch-Schönlein purpura (HSP), also known as immunoglobulin A vasculitis, is a self-limiting, small vessel systemic vasculitis rarely found in adults 
characterized by palpable purpura, arthritis or arthralgia, gastrointestinal, and renal involvement. We report a case of a 31-year-old male with HSP 
complicated with severe gastrointestinal manifestations mimicking acute abdomen. He was successfully managed with conservative approach. 
Meticulous diagnosis, treatment, and long-term monitoring are important to reduce patient morbidity.
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INTRODUCTION
Henoch-Schönlein purpura (HSP) is one of the most common 
small vessel vasculitides in children. It is characterized by non-
thrombocytopenic, leukocytoclastic vasculitis with immunoglobulin 
A (IgA) deposition [1]. However, HSP cases in adults are uncommon. 
It is also related to more severe clinical episodes and may leave long-
term target organ complications in a number of patients [1,2]. This 
prompts a meticulous investigation and management to prevent 
lasting complications. Abdominal pain is a common finding in HSP with 
varying severity; it may be easily mistaken for an acute abdomen if 
the underlying cause is overlooked. We report a case of an adult-onset 
HSP with severe gastrointestinal symptoms successfully treated with 
steroid therapy.
CASE REPORT
A 31-year-old man came to internal medicine clinic with a 2-day history 
of rash over his legs. The lesions were small at first, increasing in size 
to red plaques overnight. There were no burning sensations on the skin 
lesion; he only felt a slight non-disturbing itch. He also experienced 
diffuse abdominal pain and joint pain all over his body, without any 
limitations to movement. There were no changes in bowel habit, he 
was not nauseous, urinary complaints were absent. Significant medical 
history was a sore throat about 1 week before the skin complaints, in 
which he took medications from primary health-care center (he was 
unable to recall the drug names). He denied any previous history of 
drug allergies.
On examination, he was alert with normal vital signs. There were 
no abnormalities in the head and neck region. Respiratory and 
cardiovascular physical examinations were unremarkable. The 
abdomen was flat on inspection, bowel sound was normal, pain after 
soft palpation was noticed in all quadrants without muscle guarding, 
and no enlargement of liver and spleen was found either. Red, palpable 
purpuras were seen all over his lower extremities (Fig. 1), several 
smaller lesions were found on his elbow as well. Joint swelling or redness 
was absent. A working diagnosis of HSP was established and the patient 
was admitted to the internal medicine ward. The patient was started 
on 62.5 mg of intravenous methylprednisolone every 12 h. Ceftriaxone 
was also administered due to suspicion on secondary infection. To ease 
the joint pain, intravenous paracetamol was chosen. Laboratory tests 
revealed leukocytosis (white blood cells 15.590/uL) with neutrophilia, 
normal hemoglobin (16.5 g/dL), hematocrit (49.5%), normal platelet 
count (332.000/uL), hypoalbuminemia (3.0 g/dL), normal kidney 
function (urea 19 mg/dL, serum creatinine (0.9 mg/dL), normal alanine 
aminotransferase (48 U/L), and aspartate aminotransferase (32 U/L). 
Urinalysis result was unremarkable. Neither gross nor microscopic 
hematurias were seen, and proteinuria was absent. Dermatology 
department was consulted and topical desoximetasone + gentamycin 
ointment was added to therapy. Skin biopsy could not be done in our 
hospital due to lack of related equipment.
On the first night of admission, the patient began to feel nauseous. 
He started vomiting profusely on the following day. There was no 
blood or blood clots observed in the vomitus. 4 mg of intravenous 
ondansetron was administered every 8 h, in addition to intravenous 
esomeprazole 40 mg once daily. On the next day, the abdominal pain 
worsened with muscle guarding, which did not present before. He 
was also complaining of difficulty in defecating. Bowel movement was 
still audible with auscultation and no distention was seen. An urgent 
surgery consultation was commenced, arising suspicion of acute 
abdomen. Despite the patient’s clinical condition, the surgeon decided 
not to conduct a surgical intervention. Plain abdominal radiography 
appeared unremarkable (Fig. 2).
Abdominal distention was observed on the 4th day. On physical 
examination, shifting dullness was positive. The diffuse abdominal 
pain did not decrease in intensity. Abdominal ultrasound examination 
revealed free fluid in the abdominal cavity, pelvic cavity, and McBurney 
area (Fig. 3). Pleural effusion was also visible, although the patient never 
complained of shortness of breath and his respiratory rate was always 
normal. Over the next 3 days, the abdominal pain resolves spontaneously 
without any intervention, the patient’s abdomen was no longer distended, 
and his bowel habit returned to normal. Furthermore, the purpuric 
rashes became less visible (Fig. 4) and his joint pain became milder. The 
patient was discharged uneventfully. Oral methylprednisolone treatment 
was continued 8 mg twice daily, and he was scheduled for a follow-up 
visit to internal medicine and dermatology clinics.
DISCUSSION
HSP is a self-limiting, systemic, non-granulomatous, autoimmune 
complex, and small vessel vasculitis. It is associated with multiorgan 
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involvement [3]. Schönlein first described a syndrome of acute purpura 
and arthritis in children in 1837. Manifestations of colicky abdominal 
pain and nephritis were then added by Henoch in 1874 [4].
The exact cause of HSP is still unknown, but it is established that IgA 
has an important role in the pathophysiologic process [5]. Bacterial and 
viral infections, drugs, and autoimmune mechanisms may trigger the 
formation of antigen and antibody complex such as IgA. Streptococcal 
infection with positive antistreptolysin-O titer has been reported to 
hypothetically initiate the immune cascade in HSP. Only IgA1 is found 
in HSP. Immune complexes, including IgA deposit in small vessel walls, 
activate the complement pathway, leading to polymorphonuclear cells 
accumulation causing inflammation and vessel wall necrosis (focal 
fibrinoid necrosis) without granulomatous reaction, and with associated 
erythrocyte extravasation, consistent with a form of leukocytoclastic 
vasculitis. The aforementioned vasculitis is most likely responsible to 
the development of edema and hemorrhage [3,6]. The patient, in this 
case, has just recovered from upper respiratory tract infection, which 
might have been the trigger to HSP.
As the most common systemic vasculitis affecting children, HSP has the 
annual incidence of 3–26/100.000, most frequently found in children 
from 4 to 7 years old. In adults, the incidence of HSP is relatively 
rare with the annual incidence ranging from 0.1 to 1.8/100.000 
individuals [5]. The self-limiting nature of HSP might also mask the 
true incidence rate [3]. The overall incidence of adult-onset HSP in 
Indonesia to this date is still unclear, most probably due to the lack of 
reports or underdiagnosis.
HSP is classically characterized by tetrad of non-thrombocytopenic 
palpable purpura, arthritis or arthralgia, gastrointestinal, and renal 
involvement. Cutaneous manifestation is present in a majority of 
cases. Purpura in HSP is defined as palpable, non-blanching cutaneous 
hemorrhages >1 cm in diameter. The erythematous rashes usually 
appear in dependent areas that are subject to pressure including lower 
extremities, belt line, and buttocks. The arthritis is non-migratory, 
transient, and leaves no deformity. Abdominal pain might mimic an 
acute abdomen due to its severity. Vomiting and gastrointestinal 
bleeding are common. Occult blood may be found in the fecal 
examination. Intussusception may also occur, but it is uncommon.
There are no specific serologic tests to diagnose HSP. Elevated IgA 
level is found in the majority of cases [6-8]. Although it is not specific, 
serum IgA measurement may help physicians to distinguish HSP/
IgA vasculitis from other forms of small vessel vasculitis such as 
antineutrophil cytoplasmic antibody-associated vasculitis, Churg–
Strauss, and Wegener’s granulomatosis [3,9]. Serum IgA measurement 
was not available in our hospital; hence, the diagnosis relies heavily on 
patient history and clinical manifestations.
Routine urinalysis is vital in patients with HSP. Microscopic hematuria is 
the most sensitive finding suggestive of IgA nephropathy in the presence 
of vasculitis. In addition to hematuria, proteinuria is not uncommon 
in HSP. Renal involvements are more frequent and severe in adults 
compared to those in children [5,7]. HSP has been documented to occur 
in pregnancy. The diagnosis in this special population is challenging 
because the systemic signs and symptoms are similar to commonly 
encountered pregnancy complications such as preeclampsia. History of 
HSP during childhood is a major risk factor for developing hypertension 
and proteinuria in pregnancy [10].
In 1990, ACR proposed the first criteria to diagnose HSP derived from 
both clinical and histopathology findings. A patient is said to have HSP 
if at least two of four findings are present (Table 1), with a sensitivity of 
87.1% and specificity of 87.7% [4].
Using the 2010 EULAR/PRINTO/PRES criteria shown in Table 4, a 
patient fulfills the diagnosis of HSP when palpable purpura is present 
(mandatory), in addition to either abdominal pain, histopathology 
showing IgA deposition, the presence of arthralgia, or evidence of renal 
involvement [11].
However, the 2010 EULAR/PRINTO/PRES criteria for diagnosing HSP 
(Table 2) have its data sourced from pediatric patients, raising concerns 
it might not be suitable for use in the adult population. There was a 
study reviewing adult patients with positively diagnosed HSP from the 
2012 International Chapel Hill Consensus Conference Nomenclature 
of Vasculitides to match the ACR and EULAR criteria. The result was 
the 2010 EULAR/PRINTO/PRES criteria had a 99.2% sensitivity and 
86% specificity, compared to 86.8% sensitivity and 81% specificity 
using the 1990 ACR criteria. The better performance of 2010 EULAR/
PRINTO/PRES criteria is contributed by the addition of joint and renal 
involvements, which were not included in the old ACR criteria [12].
In our patient, a skin biopsy was not possible due to limitations in 
hospital pathologic facility, prohibiting the use of several diagnostic 
criteria where all require biopsy result to prove IgA deposition 
to distinguish the palpable purpura from other similar lesions 
such as drug-related hypersensitivity maculopapular eruption or 
ecchymosis [13-15]. This prompted the use of criteria from the 1990 
American College of Rheumatology [4] criteria and the latest 2010 
European League against Rheumatism/Paediatric Rheumatology 
International Trials Organisation/Paediatric Rheumatology European 
Society (EULAR/PRINTO/PRES) [11] to establish the working diagnosis 
of HSP in the absence of histopathology examination.
Early steroid initiation is beneficial to reduce gastrointestinal 
symptoms, prevent major complications, i.e., gastrointestinal bleeding 
or intussusception, and slow down the rate of renal progression. There 
Fig. 1: The right leg showing palpable erythematous purpuras
Fig. 2: Plain abdominal radiograph
13
Asian J Pharm Clin Res, Vol 11, Issue 11, 2018, 11-15
 Cassidy et al. 
is no strict steroid dosing regimen in HSP treatment. This depends 
highly on the clinical manifestations of HSP and the severity of the 
disease. Steroid therapy is indicated in patients with severe rash, edema, 
severe abdominal pain, and renal involvement. Oral steroid is preferred 
when tolerated, methylprednisolone 1–2 mg/kg/day for up to 2 weeks 
then tapered down to 0.5 mg/kg/day over 1 week, and 0.5 mg/kg every 
other day for another 1 week. The same principle applies to intravenous 
steroid where the patient is unable to tolerate oral drug form [3].
Methylprednisolone pulse has been reported in successfully treating 
HSP with severe gastrointestinal signs and symptoms (severe 
abdominal tenderness, obstipation, vomiting, and absent bowel 
movement) resembling intestinal ischemia [16]. A prospective trial 
in adults supported this evidence, where methylprednisolone pulses 
followed by oral prednisolone provided excellent 10-year renal survival 
compared to a control group [17]. There is a reported case of HSP 
presenting with hemorrhagic ascites and extensive bowel thickening 
in computed tomography scan. Complete resolution was achieved 
with steroid therapy, without surgical intervention [18]. Low-dose 
intravenous methylprednisolone demonstrated satisfactory result in 
this case, leading to resolution of almost all symptoms, eliminating the 
necessity for surgery. Fig. 5 shows a proposed treatment algorithm 
for managing HSP patients according to each commonly found organ 
system involvements [5].
Nonsteroidal anti-inflammatory drugs are generally avoided to 
alleviate pain in patients with renal involvement and to prevent further 
exaggerate gastrointestinal symptoms. Paracetamol is safe to use even 
in renal impairment, providing mild analgesia to reduce the arthralgia. 
Few studies showed that colchicine has decent efficacy in terms of 
reducing inflammation in patients with cutaneous leukocytoclastic 
vasculitis, but evidence is limited, and relapse has been reported after 
discontinuation of colchicine. Leukotriene receptor antagonist has 
been used in children population, relieving symptoms, and inhibiting 
relapse. At present, there is not enough evidence supporting the benefit 
of using azathioprine in adult patients. Other immunosuppressive 
drugs including cyclosporin A, mycophenolate mofetil, and 
cyclophosphamide have been used in combination with steroid therapy 
for adult patients with nephrotic range proteinuria. Remission rates 
were better compared to those receiving steroid alone, although the 
statistical power was low in some studies [5]. We decided to manage 
the bowel angina and arthralgia with paracetamol as it was deemed 
to provide mild analgesia without compromising kidney function and 
avoiding the risk of further gastrointestinal side effects of nonsteroidal 
anti-inflammatory drugs.
Fig. 3: Abdominal ultrasound, note the presence of free fluid in the abdominal cavity and pleural effusion
Table 1: ACR 1990 criteria for the classification of Henoch–
Schönlein purpura [4]
Criterion Definition
Palpable purpura Slightly raised “palpable” 
hemorrhagic skin lesions, not 
related to thrombocytopenia
Age ≤ 20 at disease onset Patients 20 years or younger at 
onset of first symptoms
Bowel angina Diffuse abdominal pain, worse after 
meals, or the diagnosis of bowel 
ischemia, usually including bloody 
diarrhea
Wall granulocytes on biopsy Histologic changes showing 
granulocytes in the walls of 
arterioles or venules
Fig. 4: Regressed palpable purpura
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Prognosis of HSP in adult is good, due to its self-limiting nature. 
Persistent renal damage is the most common complication in adult-
onset HSP. A long-term follow-up in one study reported persistent 
hematuria and renal failure needing hemodialysis in adults with HSP 
[19]. Recurrences within the first 6 months after onset are also more 
frequent in patients presenting with renal involvement. On the contrary, 
those without evidence of renal involvement at the onset of HSP may 
not develop permanent renal impairment. Blood pressure measurement 
and urinalysis should be performed in every follow-up visit.
Our patient had no episodes of macroscopic and microscopic hematuria 
throughout the hospitalization period. Serum urea and creatinine levels 
were within normal limits. In patients without any renal involvement 
such as in this case, a monthly urinalysis up to 6 months is recommended 
to facilitate early recognition of renal damage [7].
CONCLUSION
We report a case of a 31-year-old male presenting with palpable 
purpura and severe gastrointestinal symptoms diagnosed as HSP. 
Utilizing the 2010 EULAR/PRINTO/PRES criteria, the clinical diagnosis 
was established despite the lack of histopathology and serum IgA level 
examination. Despite the presence of free fluid within the abdominal 
cavity, complete resolution was achieved using intravenous steroid, 
without remaining abdominal symptoms, palpable purpura, arthralgia, 
or evidence of renal damage.
HSP is a small vessel systemic vasculitis rarely found in adults. It is a 
self-limiting disease and benign in nature. Nevertheless, severe cases 
of HSP in adults were reported from worldwide. Severe gastrointestinal 
manifestations mimicking surgical emergency may occur. Such event 
rarely requires urgent surgical intervention. Management for HSP 
varies from symptomatic treatments to immunosuppressive drugs. 
Steroid therapy was proven to be effective. Prognosis is generally 
good. Follow-up visits are needed, with blood pressure measurement 
and urinalysis every month up to 6 months to monitor recurrence 
and the possible evolution to renal impairment. This case serves as a 
reminder for physicians to increase awareness of HSP in adults. Refined 
documentations and/or studies on systemic vasculitis in Indonesia are 
highly necessary to provide better patient management.
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